Genomics England will play a key role in building on the UK’s long track record as leader in medical science advances to push the boundaries by unlocking the power of DNA data. The UK will become the first ever country to introduce this technology in its mainstream health system – leading the global race for better tests, better drugs and above all better, more personalised care.

http://www.genomicsengland.co.uk/100k-genome-project/

genomic scale studies
endogenous mechanisms of mutations, germ line and somatic
computational aspects of immunology in cancer
signalling networks
three-dimensional organization of information in the nucleus
gene silencing
metastatic cross-talk
kinase signaling
personalized medicine
detection of biomarkers in cancer
historical DNA variation

From : http://www.ous-research.no/hovig/

Group address:
Eivind Hovig, The Norwegian Radium Hospital, Montebello, 0310 Oslo,Norway
Email: ehovig@radium.uio.no

SciGenom Research Foundation (SGRF) and Institute of Genomics and Integrative Biology (IGIB) are pleased to host the Next-Generation Sequencing and Bioinformatics for Genomics & Healthcare conference.

In the ten years since the first human reference genome was completed for US$3 billion the sequencing technologies have radically changed leading to great reduction in sequencing cost. Today a human genome can be sequenced for under US$ 5000 in less than two weeks. It is expected that by the end of 2015 the cost of sequencing a human genome will drop to below thousand dollars. The next generation sequencing technologies over the past five years have enabled a large number of genomic studies that impact human health and disease. Also, this has made possible the growth of microbial, animal and plant genomics studies. While the data production has increased at a rapid pace challenges remain in analyzing and understanding the data. The conference will cover the next generation sequencing (NGS) technologies, bioinformatics for NGS and applications of NGS in many areas including personalized medicine.

For more info : http://www.scigenomconferences.com/2013/default.php

High Throughput Sequencing Analysis
Comparative Genomics
Identification and Annotation of Non-coding RNAs
Bioinformatic Analysis and System Biology of Viruses
Coevolution of Proteins and RNAs
Algorithmic Bioinformatics
Phylogenetic Analysis

http://www.rna.uni-jena.de/index.php

Candidates must have: a PhD degree in statistics, biostatistics or bioinformatics, extensive experience in analyzing high-dimensional data (microarray, SNP, CNVs) and of validation approaches. In addition, experience in penalized regression methods, data base manipulation; and strong programming skills in order to conduct Monte Carlo studies and applications (R). Candidate must have excellent communication skills (verbal, written and presentation), a strong proficiency in Linux system.

This position is available immediately and will be filled as soon as possible. Appointment could be extended beyond the first year based on additional funding.

For more information about the Department of Biostatistics and Bioinformatics, please visit our website: http://www.biostat.duke.edu.

For more info: http://biostat.duke.edu/sites/biostat.duke.edu/files/Halabi%20-%20Postdoc%20Job%20Posting%202013%20updated.pdf

Duke University is an Equal Opportunity/Affirmative Action Employer.

Address of the bookmark: http://grouthbio.com/Genome_Software_Service.php

Authors of selected high quality papers in BICoB-2015 will be invited to submit extended version of their papers for possible publication in bioinformatics journals (Journal of Bioinformatics and Computational Biology JBCB).

Deadlines:

Paper Submission Deadline October 24, 2014
Notification of Acceptance December 15, 2014
Camera-Ready Manuscript January 16, 2015

Address of the bookmark: http://www.cs.umb.edu/bicob/

11. Development of innovative tools for rapid phenotypic characterisation of intraspecific diversity of Listeria monocytogenes (Joint supervision PhD)
Host Organizations BioFilm Control (France) and GenXPRO (Germany)
Objectives
1. The ESR will develop an assay to test biofilm phenotype in a large array of food processing-related environmental conditions (salt, acides, disinfectants, preservatives) in BFC facilities. He will be in charge of the development and validation of an in silico virulence assay. This assay will target specific mRNAs in order to estimate the virulence potential of strains of L. monocytogenes. Transcript targets will be selected and tested by qPCR in GXP premises. In the process of validation, virulence results of several strains collected in a humanised mouse model will be compared with the in silico analysis. Once these innovative tools will be validated, intraspecific phenotypic diversity (biofilm and virulence) will be assessed on a collection of environmental and clinical isolates of L. monocytogenes. Genotypic diversity will be assessed under the supervision of GPX.
Expected Results : Adaptation of the BioFilm Ring test R to test food processing environmental conditions. Development of an innovative in silico virulence assay surrogate to animal models. Diversity results will inform stakeholders on the level of health hazard according to the strain. This in turn will help secure food safety all along the shelf life of foodstuff.
Duration (months) 36
Contact : Dr. Thierry BERNARDI: thbe@biofilmcontrol.com
Dr. Bjorn ROTTER: rotter@genxpro.de
ELIGIBLE CRITERIA of Marie Sklokowska Curie actions:
Researchers may be of any nationality
Candidates shall at the time of recruitment by the host organization, be in the first four years (full-time equivalent research experience) of their research careers. Full-time equivalent research experience is measured from the date when a researcher obtained the degree which would formally entitle him or her to embark on a doctorate, either in the co